Real-World Evidence: Some key learnings from 2011
In her article in the December issue of IN VIVO, “Pharma/Payor Deals An Important Step In The Shift To Value-Based R&D,” Ellen Licking examines the opportunities and challenges brought by a new generation of business relationships between pharmaceutical companies and payor organizations to gain deeper insights into a medicine’s true value.
As we near the one-year mark since we announced our agreement with HealthCore, we have learned a great deal from engaging with physician practice groups and hospitals, governments, commercial payors, health information technology consortiums and other stakeholders actively looking at how to realize the promise of real-world evidence to improve health outcomes.
Among our learnings:
- What’s the way when there is the will? There is significant interest among stakeholders from virtually every part of the health care sector to build health care data alliances. The rub is facilitating the interoperability of the different data sets and finding the resources to collect, analyze and apply the data.
- What’s in a name? The concept of “real-world evidence” means different things to different people, so it’s important to get to that place of common understanding with potential partners.
- Serving different needs. Colleagues are looking for ways to more efficiently link different data sources – medical claims, prescription claims, clinical data – to generate the insights they want in ways that meet privacy and security standards.
The IN VIVO blog is inviting readers to vote on their pharma “deal of the year,” and we’re proud that AstraZeneca/HealthCore was among the nominees. We’ll continue to share developments as we progress with this exciting new way of working with colleagues across the health care system to build a new data environment that can lead to better ways to manage the total cost of care for patients.